 BioFocus
Annual Report and Accounts 
2005
15
Directors'
remuneration report
For the 15 months ended
31 March 2005
The Board has established a Remuneration Committee which has overall responsibility for
remuneration policy and specific responsibility for determining the remuneration of the
executive directors. The members of the Remuneration Committee are David Stone, the Non-
Executive Chairman of the Company, who is Chairman of the Committee, and Brian Adger, 
a non-executive director. The Remuneration Committee has access to professional advice 
from inside and outside the group.
Policy on remuneration of executive directors
The remuneration policy in respect of executive directors is to ensure that individual
remuneration reflects the performance of the group, the performance of each director and 
the interests of shareholders and that the overall remuneration package enables the group 
to attract and retain high calibre executives. The remuneration package of executive directors
presently consists of basic salary, bonus, medical insurance, life assurance, company pension
contributions and long term incentive schemes. Bonuses are awarded on the achievement 
of pre-agreed targets.
Service and consultancy agreements
The company entered into a service agreement with Geoffrey McMillan on 4 November 2002.
This agreement may be terminated by either party giving 12 months' written notice.
On 1 January 2004 Stephen France entered into a service agreement with the company, 
which may be terminated by either party giving 12 months' written notice.
Non-executive directors
The remuneration of the non-executive directors is determined by the Board of Directors.
David Stone was appointed as Chairman on 1 May 2003. With effect from 1 January 2004 
this position became non-executive. Dr Stone's appointment may be terminated by either 
party giving three months' written notice.
On 1 November 1999 the company appointed Brian Adger as a non-executive director.
Dr Adger's appointment may be terminated by either party on three months' written notice.
On 1 December 2004 the company appointed James Cook as a non-executive director. 
Mr Cook's appointment may be terminated by either party on three months' written notice.
6157 Annual Report 2005.qxd  7/11/05  11:26 AM  Page 15 BioFocus
Annual Report and Accounts 
2005
16
Directors'
remuneration report
For the 15 months ended
31 March 2005
Continued
Directors' remuneration
The following tables show the detailed analysis of directors' remuneration:
15 months to 31 March 2005:
Total
Estimated excluding Compensation
benefits pension Pension for loss of
Salary Fees in kind contributions contributions office
 '000  '000  '000  '000  '000  '000
David Stone   41   41    
Geoffrey McMillan 250     250 25  
Stephen France 145   1 146 7  
Brian Adger   20   20    
Ian Kent   15   15   10
Mark Treherne   13   13    
James Cook   5   5    
395 94 1 490 32 10
Year to 31 December 2003:
Total
Estimated excluding Compensation
Consultancy benefits pension Pension for loss of
Salary Bonus fees Fees in kind contributions contributions office
 '000  '000  '000  '000  '000  '000  '000  '000
Norman Burden       10   10   31
David Stone 73     20   93 5  
Geoffrey McMillan 165 55     1 221 16  
Stephen France 15 3 90   1 109 5  
Brian Adger       15   15    
Ian Kent       15   15    
Mark Treherne       15   15    
253 58 90 75 2 478 26 31
Long term incentive schemes
The company established an approved Share Option Scheme in 1998. Unapproved and EMI
Option Schemes were established in 2000. The grant of options under these schemes is at the
discretion of the Remuneration Committee. Details of options granted to the directors under 
the share option schemes are shown in the directors' report.
David Stone
Chairman of the Remuneration Committee
17 June 2005
6157 Annual Report 2005.qxd  7/11/05  11:26 AM  Page 16